Erschienen in:
28.01.2019 | Editorial
Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)—a question to be addressed in a scientific way
verfasst von:
Gema Ariceta
Erschienen in:
Pediatric Nephrology
|
Ausgabe 5/2019
Einloggen, um Zugang zu erhalten
Excerpt
Atypical hemolytic uremic syndrome (aHUS) is an ultrarare disease caused, in most cases, by dysregulation of the alternative complement (C′) pathway at the surface of the vascular endothelium [
1‐
3]. Uncontrolled C′ activation due to genetic abnormalities of several regulatory proteins, such as complement factor H (FH) [
4‐
13] or auto-antibodies against FH synthesis [
14,
15], lead to increased C3 convertase production and/or reduced degradation [
16], which in turn result in excessive C5 activation, C5b-9 formation (also named terminal complement complex (TCC)), and subsequently endothelial cell lysis [
17,
18]. Independent of the individual specific C′ anomaly, aHUS is a disease driven by a common pathogenic mechanism: C5 activation [
19,
20]. …